The U.S. Patent & Trademark Office denied Medtronic‘s (NYSE:MDT) request for inter partes review of a disputed stent patent in its ongoing case against Endotach.
Medtronic filed a 2nd petition for a review of patent ‘417 in April. The 2nd petition included 3 new grounds supporting its case against Endotach.
On Sept. 25, the USPTO Patent Trial & Appeal Board ruled against Medtronic’s 2nd petition on the basis that it was not filed by the statutory deadline.
Endotach filed suit against Medtronic in late 2012, alleging the medical device giant had infringed 2 of its stent patents, including the ‘417 patent.